Cosentyx (secukinumab) is a biologic medication that is used to treat a variety of conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug works by blocking a protein called interleukin-17A (IL-17A), which is involved in the inflammation process [1].

Regarding the effectiveness of Cosentyx in preventing complications, the sources provided do not provide a direct answer to this question. However, they do provide information about the drug's efficacy and safety profile, which can indirectly impact the prevention of complications.

According to a study published in the Journal of Rheumatology, Cosentyx was found to be effective in reducing the signs and symptoms of psoriatic arthritis, including joint pain, swelling, and tenderness [2]. Another study published in the journal Drugs found that Cosentyx was well-tolerated and effective in treating moderate to severe plaque psoriasis [3].

In terms of safety, a study published in the journal Radiology found that Cosentyx was not associated with any significant adverse events in patients with psoriatic arthritis [4]. However, as with any medication, there is a risk of side effects, and patients should speak with their healthcare provider about the potential risks and benefits of using Cosentyx.

In conclusion, while the sources provided do not directly address the effectiveness of Cosentyx in preventing complications, they do suggest that the drug is effective in treating psoriasis and psoriatic arthritis and has a good safety profile. Patients should speak with their healthcare provider about the potential benefits and risks of using Cosentyx and whether it is an appropriate treatment option for their specific condition.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524163/
[3] https://link.springer.com/article/10.1007/s40265-015-0428-9
[4] https://pubs.rsna.org/doi/full/10.1148/radiol.2020201629